{"created":"2023-06-20T16:34:16.344347+00:00","id":3420,"links":{},"metadata":{"_buckets":{"deposit":"7fc2e2f0-86d9-495d-98e4-609cbfb1c355"},"_deposit":{"created_by":3,"id":"3420","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"3420"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:00003420","sets":["14:2667:2668:2987","21:2669:2670:2988"]},"author_link":["4015","4016"],"item_8_alternative_title_3":{"attribute_name":"その他（別言語等）のタイトル","attribute_value_mlt":[{"subitem_alternative_title":"Prediction of sorafenib response by FGF3 gene amplification for patients with hepatocellular carcinoma"}]},"item_8_biblio_info_21":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2014-01-01","bibliographicIssueDateType":"Issued"},"bibliographicPageEnd":"4","bibliographicPageStart":"1","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2014 )"}]}]},"item_8_description_33":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"研究成果の概要（和文): 肝細胞がんにおいて, ソラフェニブの効果を予測するFGF3, FGF4遺伝子増幅以外の新たなバイオマーカーの探索を多施設臨床研究で実施した. 収集した著効例のコピー数変動解析よりFGF19のコピー数変動を見出した. 多施設共同前向き試験として, 次世代シーケンサーを用いて肝生検FFPEサンプルを用いた遺伝子解析を実施した. DNAシーケンシングにより, 「がん遺伝子の変異の頻度」, RNAシーケンシングによりTGF-αおよびPECAM1が腫瘍縮小効果に関連するバイオマーカーとして, Neuregulin 1遺伝子発現が, 無増悪生存期間延長の予測マーカーであることを示した.          研究成果の概要（英文）： We have analyzed the copy number variation of hepatocellular carcinoma (HCC) tumor in a multicenter clinical study. We found increased copy number of FGF19 was a new predictive biomarker for sorafenib response in addition to FGF3/FGF4 gene amplification in HCC. Separately, we conducted DNA and RNA sequencing of tumor FFPE samples in another multicenter clinical trials for HCC patients treated with sorafenib. DNA amplicon sequencing and RNA sequencing targeted 50 candidate genes were performed using FFPE tumor samples obtained by liver core needle biopsy. HCC tumor with low oncogene mutation numbers were sensitive to sorafenib treatment, suggesting that oncogene mutational burden in the tumor might be associated with the clinical response to sorafenib. We have also identified candidate genes (TGF-&","subitem_description_type":"Abstract"}]},"item_8_description_36":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"研究種目：基盤研究（A）;  研究期間：2012～2014;   課題番号：24240122;   研究分野：分子生物学   科研費の分科・細目：","subitem_description_type":"Other"}]},"item_8_description_37":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Research Paper","subitem_description_type":"Other"}]},"item_8_description_41":{"attribute_name":"フォーマット","attribute_value_mlt":[{"subitem_description":"application/pdf","subitem_description_type":"Other"}]},"item_8_publisher_14":{"attribute_name":"出版者 名前","attribute_value_mlt":[{"subitem_publisher":"近畿大学"}]},"item_8_relation_11":{"attribute_name":"著者 外部リンク","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/d/r/10208134.ja.html"}]},{"subitem_relation_name":[{"subitem_relation_name_text":"https://kaken.nii.ac.jp/d/r/10298953.ja.html"}]}]},"item_8_text_10":{"attribute_name":"著者 役割","attribute_value_mlt":[{"subitem_text_value":"研究代表者"},{"subitem_text_value":"研究分担者"}]},"item_8_text_7":{"attribute_name":"著者(英)","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"NISHIO, Kazuto"},{"subitem_text_language":"en","subitem_text_value":"KUDO, Masatoshi"}]},"item_8_text_8":{"attribute_name":"著者 所属","attribute_value_mlt":[{"subitem_text_value":"近畿大学医学部; 教授"},{"subitem_text_value":"近畿大学医学部; 教授"}]},"item_8_text_9":{"attribute_name":"著者所属(翻訳)","attribute_value_mlt":[{"subitem_text_value":"Kinki University"},{"subitem_text_value":"Kinki University"}]},"item_8_version_type_12":{"attribute_name":"版","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"西尾,  和人"},{"creatorName":"ニシオ, カズト","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"工藤,  正俊"},{"creatorName":"クドウ, マサトシ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-02-17"}],"displaytype":"detail","filename":"24240122seika.pdf","filesize":[{"value":"319.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"24240122seika.pdf","url":"https://kindai.repo.nii.ac.jp/record/3420/files/24240122seika.pdf"},"version_id":"d8b4c735-f2ea-422d-b998-461cce834b8d"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"肝細胞がん","subitem_subject_scheme":"Other"},{"subitem_subject":"ソラフェニブ","subitem_subject_scheme":"Other"},{"subitem_subject":"バイオマーカー","subitem_subject_scheme":"Other"},{"subitem_subject":"TGF-α","subitem_subject_scheme":"Other"},{"subitem_subject":"PECAM1","subitem_subject_scheme":"Other"},{"subitem_subject":"NRG1","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"research report","resourceuri":"http://purl.org/coar/resource_type/c_18ws"}]},"item_title":"ＦＧＦ3遺伝子増幅による肝細胞癌ソラフェニブ治療の効果予測","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"ＦＧＦ3遺伝子増幅による肝細胞癌ソラフェニブ治療の効果予測"}]},"item_type_id":"8","owner":"3","path":["2987","2988"],"pubdate":{"attribute_name":"公開日","attribute_value":"2015-10-09"},"publish_date":"2015-10-09","publish_status":"0","recid":"3420","relation_version_is_last":true,"title":["ＦＧＦ3遺伝子増幅による肝細胞癌ソラフェニブ治療の効果予測"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-06-21T01:36:14.553673+00:00"}